Novo Nordisk A/S reported a 12% increase in sales for the first nine months of 2025, reaching DKK 229.9 billion, while the operating profit grew 5% to DKK 95.9 billion, impacted by around DKK 9 billion in restructuring costs. The company also announced an extraordinary meeting on 14 November 2025 to elect new Board members.